
David Fitchett MD
Recent Contributions to PracticeUpdate:
- Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Independently of LDL-C and Statin Use
- In High Risk Patients, Canagliflozin Reduces Risk of Cardiovascular Death and Heart Failure Hospitalization
- Risks of Cardiovascular Events and Mortality Are Lower With Dapagliflozin Than With DPP-4 Inhibitors
- Cardiovascular Effects of SGLT-2 Inhibitors in Type 2 Diabetes